Meeting Report

Blood Transfusion - 6 2019 (November-December)

Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting

Authors

Key words: pathogen reduction technologies, blood safety, infectious diseases outbreaks, blood components
Publication Date: 2019-12-10

Abstract

Pathogen reduction (PR) of selected blood components is a technology that has been adopted in practice in various ways. Although they offer great advantages in improving the safety of the blood supply, these technologies have limitations which hinder their broader use, e.g. increased costs. In this context, the European Centre for Disease Prevention and Control (ECDC), in co-operation with the Italian National Blood Centre, organised an expert consultation meeting to discuss the potential role of pathogen reduction technologies (PRT) as a blood safety intervention during outbreaks of infectious diseases for which (in most cases) laboratory screening of blood donations is not available. The meeting brought together 26 experts and representatives of national competent authorities for blood from thirteen European Union and European Economic Area (EU/EEA) Member States (MS), Switzerland, the World Health Organization, the European Directorate for the Quality of Medicines and Health Care of the Council of Europe, the US Food and Drug Administration, and the ECDC. During the meeting, the current use of PRTs in the EU/EEA MS and Switzerland was verified, with particular reference to emerging infectious diseases (see Appendix). In this article, we also present expert discussions and a common view on the potential use of PRT as a part of both preparedness and response to threats posed to blood safety by outbreaks of infectious disease.

Downloads

Authors

Dragoslav Domanović - European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Ines Ushiro-Lumb - National Transfusion Microbiology Reference Laboratory, NHS Blood and Transplant and Public Health England, London, England

Veerle Compernolle - Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium

Sergio Brusin - European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Markus Funk - Pharmacovigilance II, Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines, Langen, Germany

Pierre Gallian - Etablissement Français du Sang Provence Alpes Côte d'Azur et Corse, Marseille, France

Jørgen Georgsen - South Danish Transfusion Service, Department of Clinical Immunology, Odense University Hospital, Odense, Denmark

Mart Janssen - Department of Donor Medicine Research, Transfusion Technology Assessment, Sanquin Research, Amsterdam, The Netherlands

Teresa Jimenez-Marco - Balearic Islands Blood and Tissue Bank Foundation, Palma de Mallorca, Spain

Folke Knutson - Clinical Immunology and Transfusion Medicine IGP, Uppsala University, Uppsala, Sweden

Giancarlo M. Liumbruno - Italian National Blood Centre, National Institute of Health, Rome

Polonca Mali - Blood Transfusion Center of Slovenia, Ljubljana, Slovenia

Giuseppe Marano - Italian National Blood Centre, National Institute of Health, Rome

Yuyun Maryuningsih - World Health Organization, Geneva, Switzerland

Christoph Niederhauser - Interregional Blood Transfusion Swiss Red Cross, Laboratory Diagnostics, Bern, Switzerland

Constantina Politis - Hellenic Coordinating Hemovigilance Center, Hellenic National Public Health Organization, Athens, Greece

Simonetta Pupella - Italian National Blood Centre, National Institute of Health, Rome

Guy Rautmann - European Directorate for the Quality of Medicines and HealthCare, Strasbourg, France

Karmin Saadat - Austrian Agency for Health and Food Safety, Wien, Austria

Imad Sandid - French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France

Ana P. Sousa - Portuguese Blood and Transplantation Center, Lisbon, Portugal

Stefania Vaglio - Italian National Blood Centre, National Institute of Health, Rome

Claudio Velati - Italian National Blood Centre, National Institute of Health, Rome

Nicole Verdun - Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA, Silver Spring, United States of America

Miguel Vesga - Basque Center for Transfusion and Human Tissues/Spanish Scientific Committee for Transfusion Safety, Galdakao, Spain

Paolo Rebulla - IRCCS Foundation Ca' Granda Maggiore Policlinico Hospital, Milan, Italy

  • Abstract viewed - 4 times
  • PDF downloaded - 1 times